CG Oncology, Inc. Common stock (CGON)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.65B
Last updated: Nov 17, 2026 at 11:05 AM ET
CG Oncology, Inc. Common stock (CGON) Competitors
The companies most similar to CG Oncology, Inc. Common stock are Cogent Biosciences (COGT), TG Therapeutics (TGTX) and Tango Therapeutics (TNGX). By market cap, CG Oncology, Inc. Common stock ranks 7th of the 13 companies on this page; Vaxcyte (PCVX) is the largest at $10.03B. The median P/E of the 3 companies with a P/E is 87.2x.
Peer Comparison
CGON's ROIC of -21.1% is above the peer median of -66.0%, and its revenue growth of -3.7% is below the median of 16.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| CG Oncology, Inc. Common stock (CGON) | $6.65B | N/A | N/A | 0.0% | -21.1% | -3.7% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Tango Therapeutics Inc (TNGX) | $4.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Cytokinetics Inc (CYTK) | $7.82B | N/A | 65.3x | 0.0% | -66.0% | 2357.0% | 0.00% |
| Erasca Inc (ERAS) | $5.50B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Abivax SA American Depositary Shares (ABVX) | $7.67B | N/A | N/A | 0.0% | -159.6% | -6.8% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Immunovant Inc (IMVT) | $7.07B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| Immunitybio Inc (IBRX) | $6.40B | N/A | 30.3x | 0.0% | -780.5% | 52.3% | 0.00% |
| Vaxcyte Inc (PCVX) | $10.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Protagonist Therapeutics Inc (PTGX) | $8.55B | 27.7x | 15.8x | 62.0% | N/A | 5724.0% | 0.00% |
| Peer median | $6.74B | 87.2x | 13.4x | 0.0% | -66.0% | 16.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to CG Oncology, Inc. Common stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Tango Therapeutics Inc (TNGX) | Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation... | TNGX competitors |
| Cytokinetics Inc (CYTK) | Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering... | CYTK competitors |
| Erasca Inc (ERAS) | Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers... | ERAS competitors |
| Abivax SA American Depositary Shares (ABVX) | Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. | ABVX competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Immunovant Inc (IMVT) | Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. | IMVT competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| Immunitybio Inc (IBRX) | ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose... | IBRX competitors |
| Vaxcyte Inc (PCVX) | Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. | PCVX competitors |
| Protagonist Therapeutics Inc (PTGX) | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical... | PTGX competitors |
Frequently Asked Questions About CGON
Who are CG Oncology, Inc. Common stock's main competitors?
The companies most similar to CG Oncology, Inc. Common stock include Cogent Biosciences (COGT), TG Therapeutics (TGTX), Tango Therapeutics (TNGX), Cytokinetics (CYTK) and Erasca (ERAS), listed from the closest match.
Who is CG Oncology, Inc. Common stock's biggest competitor?
Vaxcyte (PCVX) is the largest of the similar companies at $10.03B; Cogent Biosciences (COGT) is the closest match by business profile, size, sector and industry.
How does CGON stock compare with its competitors?
CGON's net margin is 0.0% against a peer median of 0.0%.
Which of CG Oncology, Inc. Common stock's competitors pays a higher dividend?
CG Oncology, Inc. Common stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is CG Oncology, Inc. Common stock bigger than its competitors?
No. CG Oncology, Inc. Common stock is 7th by market cap among the 13 companies on this page; the largest is Vaxcyte (PCVX) at $10.03B.
CGON pages: Overview, Earnings, Forecast, Financials, Competitors